Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function

A higher rate of clinical events in poor clopidogrel and/or aspirin responders was documented by using different methods to measure platelet function, but no conclusive data about the appropriate methodology to explore platelet reactivity are available. A total of 746 patients included in the cohort...

Full description

Saved in:
Bibliographic Details
Published inThrombosis and haemostasis Vol. 100; no. 6; p. 1136
Main Authors Gori, Anna Maria, Marcucci, Rossella, Paniccia, Rita, Giusti, Betti, Fedi, Sandra, Antonucci, Emilia, Buonamici, Piergiovanni, Antoniucci, David, Gensini, Gian Franco, Abbate, Rosanna
Format Journal Article
LanguageEnglish
Published Germany 01.12.2008
Subjects
Online AccessGet more information

Cover

Loading…
Abstract A higher rate of clinical events in poor clopidogrel and/or aspirin responders was documented by using different methods to measure platelet function, but no conclusive data about the appropriate methodology to explore platelet reactivity are available. A total of 746 patients included in the cohort of the RECLOSE trial who had successful drug-eluting stent implantation were assessed for post-treatment residual platelet reactivity (RPR) in platelet-rich plasma by 10 microM adenosine 5'-diphosphate (ADP), 1 mM arachidonic acid (AA) and 2 microg/ml collagen-induced platelet aggregation and in whole blood by the PFA-100 system. At six-month follow-up, RPR by two stimuli (ADP and AA or ADP and collagen) and by three stimuli (ADP, AA and collagen) is significantly associated with higher percentage of primary (definite or probable stent thrombosis) and secondary (cardiac mortality and stent thrombosis) end-points than RPR by ADP, AA, collagen and PFA-100 system. According to the primary and secondary end points, the specificity values for RPR identified by two (ADP and AA:94%; ADP and collagen:97%) and three stimuli were higher with respect to RPR by ADP (88%), or RPR by AA (83%) or RPR by collagen (90%). The positive likelihood ratio values of RPR by three stimuli (9.55) or of RPR by ADP and collagen (8.08) were higher than those of RPR by ADP (2.59), by AA (2.05), by collagen (4.73), or by PFA-100 (2.63). This prospective study documents that the evaluation of platelet reactivity addressed to identify patients at risk of thrombotic events on dual antiplatelet treatment has to be carried out by methods able to explore different pathways.
AbstractList A higher rate of clinical events in poor clopidogrel and/or aspirin responders was documented by using different methods to measure platelet function, but no conclusive data about the appropriate methodology to explore platelet reactivity are available. A total of 746 patients included in the cohort of the RECLOSE trial who had successful drug-eluting stent implantation were assessed for post-treatment residual platelet reactivity (RPR) in platelet-rich plasma by 10 microM adenosine 5'-diphosphate (ADP), 1 mM arachidonic acid (AA) and 2 microg/ml collagen-induced platelet aggregation and in whole blood by the PFA-100 system. At six-month follow-up, RPR by two stimuli (ADP and AA or ADP and collagen) and by three stimuli (ADP, AA and collagen) is significantly associated with higher percentage of primary (definite or probable stent thrombosis) and secondary (cardiac mortality and stent thrombosis) end-points than RPR by ADP, AA, collagen and PFA-100 system. According to the primary and secondary end points, the specificity values for RPR identified by two (ADP and AA:94%; ADP and collagen:97%) and three stimuli were higher with respect to RPR by ADP (88%), or RPR by AA (83%) or RPR by collagen (90%). The positive likelihood ratio values of RPR by three stimuli (9.55) or of RPR by ADP and collagen (8.08) were higher than those of RPR by ADP (2.59), by AA (2.05), by collagen (4.73), or by PFA-100 (2.63). This prospective study documents that the evaluation of platelet reactivity addressed to identify patients at risk of thrombotic events on dual antiplatelet treatment has to be carried out by methods able to explore different pathways.
Author Gensini, Gian Franco
Gori, Anna Maria
Abbate, Rosanna
Paniccia, Rita
Antonucci, Emilia
Buonamici, Piergiovanni
Fedi, Sandra
Marcucci, Rossella
Giusti, Betti
Antoniucci, David
Author_xml – sequence: 1
  givenname: Anna Maria
  surname: Gori
  fullname: Gori, Anna Maria
  email: am.gori@dac.unifi.it
  organization: Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy. am.gori@dac.unifi.it
– sequence: 2
  givenname: Rossella
  surname: Marcucci
  fullname: Marcucci, Rossella
– sequence: 3
  givenname: Rita
  surname: Paniccia
  fullname: Paniccia, Rita
– sequence: 4
  givenname: Betti
  surname: Giusti
  fullname: Giusti, Betti
– sequence: 5
  givenname: Sandra
  surname: Fedi
  fullname: Fedi, Sandra
– sequence: 6
  givenname: Emilia
  surname: Antonucci
  fullname: Antonucci, Emilia
– sequence: 7
  givenname: Piergiovanni
  surname: Buonamici
  fullname: Buonamici, Piergiovanni
– sequence: 8
  givenname: David
  surname: Antoniucci
  fullname: Antoniucci, David
– sequence: 9
  givenname: Gian Franco
  surname: Gensini
  fullname: Gensini, Gian Franco
– sequence: 10
  givenname: Rosanna
  surname: Abbate
  fullname: Abbate, Rosanna
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19132241$$D View this record in MEDLINE/PubMed
BookMark eNo1j8tOwzAURL0oog_YsUb-gcD1I46zRBVQpEpsyrpy7OvGNHUixwX17ymv1UhnjkaaOZnEPiIhNwzuGFNwv1mBLkAVICo5ITMQEgrFZTkl83F8B2BK1uUlmbKaCc4lm5H9pk39oelzsBQ_MOaRhkjbsGtpCuOeDiaHH2oS0iGhCzajo83pbJvueG7jjrrgPaaz9q23n-Y00t7ToTMZO8zUH6PNoY9X5MKbbsTrv1yQt6fHzXJVrF-fX5YP68IqrXPhNGonHVohjC1NXbnaV0ZZV1Vau4YbEChLyz1Aw4RzVnt0umGKW2gsAF-Q29_d4dgc0G2HFA4mnbb_r_kXT-JcJg
CitedBy_id crossref_primary_10_1160_TH10_11_0715
crossref_primary_10_1517_17425251003598878
crossref_primary_10_1016_j_jacc_2011_02_040
crossref_primary_10_1016_j_psyneuen_2010_08_010
crossref_primary_10_1160_TH16_04_0316
crossref_primary_10_1161_CIRCULATIONAHA_111_085464
crossref_primary_10_1309_AJCPTE3K1SGAPOIZ
crossref_primary_10_1160_TH11_04_0226
crossref_primary_10_1007_s11239_010_0533_x
crossref_primary_10_1124_jpet_114_215616
crossref_primary_10_1016_j_trprot_2013_04_002
crossref_primary_10_1161_CIRCULATIONAHA_111_075242
crossref_primary_10_1161_CIR_0b013e3181d8d929
crossref_primary_10_1111_j_1751_553X_2012_01428_x
crossref_primary_10_3310_hta19370
crossref_primary_10_1016_j_ejvs_2018_06_032
crossref_primary_10_1016_j_ijcard_2012_09_132
crossref_primary_10_3109_09537104_2013_815340
crossref_primary_10_1097_CCM_0b013e3181de8b1e
crossref_primary_10_1111_j_1472_8206_2008_00674_x
crossref_primary_10_1111_jth_12538
crossref_primary_10_4103_ijmr_IJMR_782_17
crossref_primary_10_1053_j_jvca_2010_04_017
crossref_primary_10_1016_j_ijcard_2012_05_080
crossref_primary_10_1160_TH11_03_0202
crossref_primary_10_1016_j_ejim_2015_12_003
crossref_primary_10_1016_j_jacc_2014_05_049
crossref_primary_10_3109_00365513_2012_666565
crossref_primary_10_1111_j_1538_7836_2010_04144_x
crossref_primary_10_1155_2012_617098
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1160/TH08-06-0374
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 19132241
Genre Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
.GJ
0R~
0VX
123
1KJ
4.4
53G
5RE
AAQQT
ABJNI
ABOCM
ACGFO
ACGFS
ACNUY
AENEX
AFFNX
AGCGI
AHRSK
ALMA_UNASSIGNED_HOLDINGS
BR6
C45
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EIF
EJD
F5P
H13
J5H
NPM
OVD
P2P
RTC
RTE
SJN
TEORI
X7M
ZGI
ZXP
ID FETCH-LOGICAL-c688t-d8e8d4dec33ac5a97d9f7a6cd7788db2a03e45c2f00b13ddc8fed8b162c0bc002
ISSN 0340-6245
IngestDate Mon Jul 21 06:05:17 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c688t-d8e8d4dec33ac5a97d9f7a6cd7788db2a03e45c2f00b13ddc8fed8b162c0bc002
OpenAccessLink http://www.thieme-connect.de/products/ejournals/pdf/10.1160/TH08-06-0374.pdf
PMID 19132241
ParticipantIDs pubmed_primary_19132241
PublicationCentury 2000
PublicationDate 2008-12-01
PublicationDateYYYYMMDD 2008-12-01
PublicationDate_xml – month: 12
  year: 2008
  text: 2008-12-01
  day: 01
PublicationDecade 2000
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle Thrombosis and haemostasis
PublicationTitleAlternate Thromb Haemost
PublicationYear 2008
References 19132217 - Thromb Haemost. 2008 Dec;100(6):962-4
References_xml – reference: 19132217 - Thromb Haemost. 2008 Dec;100(6):962-4
SSID ssj0016495
Score 2.1270394
Snippet A higher rate of clinical events in poor clopidogrel and/or aspirin responders was documented by using different methods to measure platelet function, but no...
SourceID pubmed
SourceType Index Database
StartPage 1136
SubjectTerms Adenosine Diphosphate
Aged
Aged, 80 and over
Angioplasty, Balloon, Coronary - adverse effects
Angioplasty, Balloon, Coronary - instrumentation
Arachidonic Acid
Aspirin - therapeutic use
Collagen - metabolism
Drug Resistance
Drug Therapy, Combination
Drug-Eluting Stents
Female
Humans
Likelihood Functions
Male
Middle Aged
Platelet Aggregation - drug effects
Platelet Aggregation Inhibitors - therapeutic use
Platelet Function Tests - instrumentation
Platelet Function Tests - methods
Point-of-Care Systems
Predictive Value of Tests
Prospective Studies
Reproducibility of Results
Risk Assessment
Risk Factors
ROC Curve
Thrombosis - blood
Thrombosis - diagnosis
Thrombosis - etiology
Thrombosis - prevention & control
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Title Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function
URI https://www.ncbi.nlm.nih.gov/pubmed/19132241
Volume 100
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Bb9MwFLa6IaFd0MbYYDDkA7cpI01SxzkiBKuQxqmTdpvsZ4cFaFK1mdD4HfzgvWcnbjZtGnCJWjtK23xf7Wfne99j7J0wkGmcRyITqyLKclFECiOJqLAmI1WNlgklJ59-FdOz7Mv55Hw0-jNQLV21-hh-35tX8j-oYhviSlmy_4BsuCg24GvEF4-IMB7_EuNlM9cNea46IyanbSUDYq8Y7zxTV0ek7los6ZFM6wPO3uO7_hYqpLR0-uUvde20HYufGIMipEc07wXsvt_6WLIyoW33S2XnDQaZqyrE5-S27-WStaJ0oCoM_vgGrgAqr-perawvetQ9xqor7PLhbNWG9pOKSo45Jtq2rW5tVMiB6KNL0KJMg8S7R4bBN44HLBsOpVRs5v4xXpAocjYl3YaIyD9neBoitJg7vHElmlKA8njvHcftvmuDbeDag4qp0g5Q92RKZK6ST_gxfTKFiN8Pv5Izo_WXubNgcYHLbJs961Yc_IOnzw4b2fo5e3raaSp22Y81i7hnEa9qTizixCLes4gji3hgEdfXfM0iHljEexbxpuQ9i3jPohfs7POn2cdp1JXgiEBI2UZGWmkyYyFNFUxUkZuizJUAk-dSGp2oOLXZBJIyjvU4NQZkaY3UY5FArAFn2z22WTe1fcm4KXIJclxanGMzleaFLA0YI8cWMOqU8Irt-9t0sfA-Kxf9DTx4sOc121oz7Q17UuIf2x5ilNjqtw62G0xxaxc
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thrombotic+events+in+high+risk+patients+are+predicted+by+evaluating+different+pathways+of+platelet+function&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Gori%2C+Anna+Maria&rft.au=Marcucci%2C+Rossella&rft.au=Paniccia%2C+Rita&rft.au=Giusti%2C+Betti&rft.date=2008-12-01&rft.issn=0340-6245&rft.volume=100&rft.issue=6&rft.spage=1136&rft_id=info:doi/10.1160%2FTH08-06-0374&rft_id=info%3Apmid%2F19132241&rft_id=info%3Apmid%2F19132241&rft.externalDocID=19132241
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-6245&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-6245&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-6245&client=summon